| Browse |
| Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants. |
| Lineage (WHO label)   | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |
|---|---|---|---|---|---|---|---|---|---|---|
| B.1.1.139 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.508 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.94 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.463 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.357 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.318 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.557 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.119 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.160 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| D.4 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.447 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.110.2 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.180 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.155 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.92 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.145 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.120 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.77 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| AE.5 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.504 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| AE.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.201 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.221 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.410 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.411 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.109 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.361 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.177.38 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| A.12 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.1.417 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.79.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XBB.1.47 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BF.7.18 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XAY.1.2 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BQ.1.1.55 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BY.1.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| EA.2 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XJ | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BR.5 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XBF.8 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.1.29 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| CL.1.2 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XBF.8.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XAU | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XAY.1.1.2 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.25.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XAD | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XAB | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| CH.1.1.4 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| FT.4 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| Lineage (WHO label) | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |